[go: up one dir, main page]

MX345032B - Antagonistas del receptor ep4 para el tratamiento de cáncer. - Google Patents

Antagonistas del receptor ep4 para el tratamiento de cáncer.

Info

Publication number
MX345032B
MX345032B MX2011011058A MX2011011058A MX345032B MX 345032 B MX345032 B MX 345032B MX 2011011058 A MX2011011058 A MX 2011011058A MX 2011011058 A MX2011011058 A MX 2011011058A MX 345032 B MX345032 B MX 345032B
Authority
MX
Mexico
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
cancer
treatment
Prior art date
Application number
MX2011011058A
Other languages
English (en)
Other versions
MX2011011058A (es
Inventor
Take Yukinori
Koizumi Shinichi
Okumura Takako
Nonomura Kazuhiko
Original Assignee
Raqualia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raqualia Pharma Inc filed Critical Raqualia Pharma Inc
Publication of MX2011011058A publication Critical patent/MX2011011058A/es
Publication of MX345032B publication Critical patent/MX345032B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invención provee un medicamento para el tratamiento de cáncer, el cual causa una reducción del cáncer. Esta invención se relaciona con el uso de un compuesto el cual tiene actividades inhibidoras en contra el receptor de prostaglandina E2 (receptor EP4) y es representado por la siguiente formula general (I), (II), (III), o (IV), o una sal farmacéuticamente aceptable de éste, o una composición farmacéutica que comprende el compuesto o la sal para la fabricación de un medicamento para el tratamiento de cáncer. La invención se relaciona con un método para el tratamiento de cáncer que comprende administrar el compuesto o una sal farmacéuticamente aceptable de éste, o una composición farmacéutica que comprende el compuesto o la sal a humanos o animales. El compuesto o una sal farmacéuticamente aceptable de éste, o la composición farmacéutica pueden ser usadas en combinación con uno o más agentes activos secundarios. (ver fórmulas).
MX2011011058A 2009-04-22 2010-04-22 Antagonistas del receptor ep4 para el tratamiento de cáncer. MX345032B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009104568 2009-04-22
JP2010015445 2010-01-27
PCT/JP2010/057114 WO2010123049A1 (ja) 2009-04-22 2010-04-22 癌治療のための選択的ｅｐ４受容体拮抗物質

Publications (2)

Publication Number Publication Date
MX2011011058A MX2011011058A (es) 2011-11-18
MX345032B true MX345032B (es) 2017-01-12

Family

ID=43011165

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2011011058A MX345032B (es) 2009-04-22 2010-04-22 Antagonistas del receptor ep4 para el tratamiento de cáncer.
MX2016008394A MX369117B (es) 2009-04-22 2010-04-22 Antagonistas del receptor ep4 para el tratamiento de cancer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2016008394A MX369117B (es) 2009-04-22 2010-04-22 Antagonistas del receptor ep4 para el tratamiento de cancer.

Country Status (12)

Country Link
US (5) US8921391B2 (es)
EP (3) EP3431085B1 (es)
JP (1) JP5668219B2 (es)
KR (1) KR101575706B1 (es)
CN (2) CN105596320B (es)
BR (1) BRPI1014174B8 (es)
CA (1) CA2754702C (es)
ES (3) ES2698508T3 (es)
HK (2) HK1166700A1 (es)
MX (2) MX345032B (es)
RU (1) RU2563817C2 (es)
WO (1) WO2010123049A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX345032B (es) 2009-04-22 2017-01-12 Raqualia Pharma Inc Antagonistas del receptor ep4 para el tratamiento de cáncer.
RU2708374C2 (ru) * 2014-05-23 2019-12-06 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Комбинированная терапия для лечения рака
US10342785B2 (en) 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
CN107383004B (zh) * 2017-07-05 2020-04-17 浙江大学 2-氨基咪唑并吡啶类衍生物及制备和应用
CA3096546A1 (en) * 2018-04-16 2019-10-24 Arrys Therapeutics, Inc. Ep4 inhibitors and use thereof
CN113301896A (zh) * 2018-07-11 2021-08-24 阿瑞斯医疗有限公司 Ep4抑制剂和其合成
CA3113468A1 (en) * 2018-09-27 2020-04-02 Arrys Therapeutics, Inc. Grapiprant unit dosage forms
EP3860998B1 (en) 2018-10-05 2023-12-27 Annapurna Bio Inc. Compounds and compositions for treating conditions associated with apj receptor activity
EP3983412A4 (en) * 2019-06-11 2023-12-27 Teon Therapeutics, Inc. PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND THEIR USES

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1304318A (zh) * 1999-03-16 2001-07-18 东丽株式会社 前列腺素ep4受体作用药和治疗方法
DE60032524T2 (de) 1999-08-10 2007-07-05 Glaxo Group Ltd., Greenford EP4 Rezeptor Ligand und Verwendung gegen neuropathischen Schmerzen, Colon Krebs, HIV und Migräne
WO2001062708A1 (fr) * 2000-02-22 2001-08-30 Ono Pharmaceutical Co., Ltd. Derives d'acide benzoique, procede de production desdits derives, et medicament contenant ces derives comme principe actif
US6710205B2 (en) 2000-02-22 2004-03-23 Ono Pharmaceutical Co., Ltd. Benzoic acid derivatives, processes for producing the same and drugs containing the same as the active ingredient
HN2001000224A (es) * 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
MXPA04009961A (es) 2002-04-12 2004-12-13 Pfizer Compuestos de imidazol como agentes anti-inflamatorios y analgesicos.
EP1494669A1 (en) 2002-04-16 2005-01-12 Fujisawa Pharmaceutical Co., Ltd. Medicament for preventing and/or treating chronic rejection
CA2536870C (en) 2003-09-03 2009-10-27 Pfizer Inc. Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
JP2007533723A (ja) * 2004-04-20 2007-11-22 ファイザー・プロダクツ・インク α２δリガンドを含む組合せ
EP1756042B8 (en) 2004-05-04 2014-06-04 RaQualia Pharma Inc Substituted methyl aryl or heteroaryl amide compounds
MXPA06012830A (es) 2004-05-04 2007-01-26 Pfizer Compuestos de aril- o heteroaril-amida ortosustituidos.
CN101137656B (zh) 2005-03-11 2010-12-22 拉夸里亚创药株式会社 咪唑衍生物的晶型
CA2608214C (en) 2005-05-19 2013-08-20 Merck Frosst Canada Ltd. Quinoline derivatives as ep4 antagonists
MX345032B (es) * 2009-04-22 2017-01-12 Raqualia Pharma Inc Antagonistas del receptor ep4 para el tratamiento de cáncer.
KR101539436B1 (ko) 2013-12-30 2015-07-24 주식회사 효성 가스 절연 개폐기의 부분 방전 검출 장치

Also Published As

Publication number Publication date
ES2698508T3 (es) 2019-02-05
EP3431085B1 (en) 2023-10-11
US10611761B2 (en) 2020-04-07
CN102421429A (zh) 2012-04-18
BRPI1014174B8 (pt) 2021-05-25
HK1214763A1 (zh) 2016-08-05
KR20120096402A (ko) 2012-08-30
EP2965756A1 (en) 2016-01-13
CA2754702A1 (en) 2010-10-28
RU2563817C2 (ru) 2015-09-20
US20150111920A1 (en) 2015-04-23
BRPI1014174A2 (pt) 2016-04-05
CA2754702C (en) 2016-06-07
MX369117B (es) 2019-10-28
EP3431085A1 (en) 2019-01-23
EP2422779B1 (en) 2016-01-06
US9688674B2 (en) 2017-06-27
MX2011011058A (es) 2011-11-18
US10947235B2 (en) 2021-03-16
EP2422779A1 (en) 2012-02-29
CN105596320B (zh) 2019-03-22
HK1166700A1 (zh) 2012-11-09
EP2965756B1 (en) 2018-10-10
US20170253595A1 (en) 2017-09-07
KR101575706B1 (ko) 2015-12-10
ES2960438T3 (es) 2024-03-04
EP2422779A4 (en) 2013-06-19
US20120088723A1 (en) 2012-04-12
CN102421429B (zh) 2016-08-17
CN105596320A (zh) 2016-05-25
ES2562814T3 (es) 2016-03-08
WO2010123049A1 (ja) 2010-10-28
EP3431085C0 (en) 2023-10-11
US20220073510A1 (en) 2022-03-10
JPWO2010123049A1 (ja) 2012-10-25
US11840530B2 (en) 2023-12-12
BRPI1014174B1 (pt) 2020-10-06
JP5668219B2 (ja) 2015-02-12
US20200188367A1 (en) 2020-06-18
US8921391B2 (en) 2014-12-30

Similar Documents

Publication Publication Date Title
MX345032B (es) Antagonistas del receptor ep4 para el tratamiento de cáncer.
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
NZ602510A (en) Treatment of lupus nephritis using laquinimod
PH12015501678B1 (en) Inhibitors of influenza viruses replication
MX338554B (es) Compuestos de fenil carbamato para usarse en aliviar o tratar el dolor.
NZ563774A (en) Inhibitors of VEGF receptor and HGF receptor signaling
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
MX2013006846A (es) Inhibidores de la replicacion de los virus de la influenza.
MX2011009709A (es) Compuestos para el tratamiento de la inflamacion y del dolor.
MX2013012588A (es) Inhibidores de cinasa.
MX2011013201A (es) Composiciones para tratar adiccion a drogas y para mejorar comportamiento relacionado a la adiccion.
MX2010009623A (es) Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
MX2011008910A (es) Derivados de azol sustituidos, composicion farmaceutica que comprende los derivados, y uso de los derivados para tratar enfermeda de parkinson.
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
NZ595767A (en) Composition for the treatment of prostate cancer
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
TNSN07419A1 (en) Methods for treating drug resistant cancer
NZ599265A (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
TN2014000031A1 (en) Use of organic compound for the treatment of noonan syndrome
TNSN08506A1 (en) Substituted carboxamides
WO2009019708A3 (en) Pharmaceutical compositions and methods for the treatment of cancer

Legal Events

Date Code Title Description
FG Grant or registration